Marker Therapeutics (NASDAQ:MRKR) Now Covered by Analysts at LADENBURG THALM/SH SH

Investment analysts at LADENBURG THALM/SH SH started coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a research report issued on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. LADENBURG THALM/SH SH’s target price would suggest a potential upside of 167.64% from the company’s previous close.

Marker Therapeutics Stock Up 1.5 %

Shares of MRKR stock opened at $4.11 on Tuesday. Marker Therapeutics has a 52-week low of $0.95 and a 52-week high of $9.68. The company has a 50-day simple moving average of $4.28 and a two-hundred day simple moving average of $3.98.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Marker Therapeutics stock. International Assets Investment Management LLC grew its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,000 shares of the company’s stock after acquiring an additional 10,000 shares during the period. International Assets Investment Management LLC owned about 0.12% of Marker Therapeutics worth $60,000 at the end of the most recent reporting period. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells.